molecular testing beyond egfr and alk in stage iv nsclc
Published 7 years ago • 489 plays • Length 4:27Download video MP4
Download video MP3
Similar videos
-
43:43
webinar: going beyond egfr: evaluating technologies for molecular genetic testing in nsclc
-
6:08
molecular testing in stage iv lung cancer
-
3:36
testing and recommendations: egfr-mutated stage iv nsclc
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
5:37
braf molecular testing in nsclc
-
16:27
debate: molecular profiling beyond egfr/alk - must be the standard
-
5:21
molecular testing and actionable targets in lung cancer
-
40:57
expanding her2 horizons: implications for nsclc and beyond
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
3:12
diagnosis of metastatic alk-rearranged nsclc
-
12:05
debate: molecular profiling beyond egfr/alk - not for everyone
-
1:15
molecular testing recommendations for nsclc
-
1:04
molecular testing in egfr mutant driven nsclc
-
4:28
mutation testing for advanced lung cancer
-
8:25
egfr & alk/ros1 testing in squamous nsclc
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
5:07
how is molecular testing used to select upfront therapy in patients with egfr mutations?
-
43:35
maximizing the impact of egfr-targeted therapy in resectable nsclc
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing